Clinical Trials in San Francisco

Showing 1361-1380 of 6,211 trials

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

NCT03266627

Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

AdenovirusPrimary Immune Deficiency Disorder

New York Medical College20 participantsStarted Nov 2018

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +7 more locations

RECRUITINGPHASE2< 1 mile

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

NCT03990896

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

Breast Cancer

Massachusetts General Hospital30 participantsStarted Nov 2021

San Francisco, California, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +4 more locations

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Find Trials by Condition in San Francisco

Optimizing Provider Training in Eating Disorders (OPTED)

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

SLC13A5 Deficiency Natural History Study - United States Only

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis